Cargando...
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia
Antibody–drug conjugates (ADCs) are likely to make a significant contribution in the treatment of acute lymphoblastic leukemia (ALL) by combining the cytotoxicity of chemotherapy with the specificity of monoclonal antibodies. CD22, an endocytic receptor expressed by the majority of B cells, is an ex...
Gardado en:
| Publicado en: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4556970/ https://ncbi.nlm.nih.gov/pubmed/26425338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620715596715 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|